Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVHPOX)

• Drug Name: AGN-242266 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-alcoholic steatohepatitis	DB92.1	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMVHPOX

Molecule-Related Drug Atlas

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[2]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[3]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[4]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[5]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[6]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[7]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[8]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[9]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[10]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[1]

References

• [1] Clinical pipeline report, company report or official report of AbbVie.
• [2] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [3] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [4] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [5] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [6] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [7] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [8] Clinical pipeline report, company report or official report of ENYO Pharma.
• [9] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [10] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [11] Clinical pipeline report, company report or official report of Metacrine.